Responses
Immune cell therapies and immune cell engineering
Original research
Combinatorial immunotherapy of N-803 (IL-15 superagonist) and dinutuximab with ex vivo expanded natural killer cells significantly enhances in vitro cytotoxicity against GD2+ pediatric solid tumors and in vivo survival of xenografted immunodeficient NSG mice
Compose a Response to This Article
Other responses
No responses have been published for this article.